Cowen analyst Ryan Blicker reiterated an Outperform rating and $85.00 price target on Tandem Diabetes Care (NASDAQ: TNDM) after it was disclosed that TNDM will be covered on an in-network basis by UnitedHealthcare starting July 1.

"The bias was already to the upside vs. revenue estimates, and UNH coverage could add 5%+ to 2020/2021 revenue expectations," Blicker commented. "We expect Control-IQ to continue driving material share gains. Estimates should continue moving higher."

The firm's price target is under review.

For an analyst ratings summary and ratings history on Tandem Diabetes Care click here. For more ratings news on Tandem Diabetes Care click here.

Shares of Tandem Diabetes Care closed at $87.81 yesterday.